Table of Content

1 Report Overview
1.1 Klebsiella Pneumoniae Infection Drug Definition
1.2 Market by Type
1.2.1 Global Klebsiella Pneumoniae Infection Drug Market Size Growth Rate by Type, 2018 VS 2024 VS 2034
1.2.2 ATI-1503
1.2.3 CA-824
1.2.4 CC-1807
1.2.5 Cefiderocol
1.2.6 Debio-1454
1.2.7 EBX-004
1.2.8 Others
1.3 Market Segment by Application
1.3.1 Global Klebsiella Pneumoniae Infection Drug Market Size Growth Rate by Application, 2018 VS 2024 VS 2034
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Klebsiella Pneumoniae Infection Drug Sales
2.1 Global Klebsiella Pneumoniae Infection Drug Revenue Estimates and Forecasts 2018-2034
2.2 Global Klebsiella Pneumoniae Infection Drug Revenue by Region: 2018 VS 2024 VS 2034
2.3 Global Klebsiella Pneumoniae Infection Drug Revenue by Region
2.3.1 Global Klebsiella Pneumoniae Infection Drug Revenue by Region (2018-2023)
2.3.2 Global Klebsiella Pneumoniae Infection Drug Revenue by Region (2024-2034)
2.4 Global Klebsiella Pneumoniae Infection Drug Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Klebsiella Pneumoniae Infection Drug Sales Quantity by Region: 2018 VS 2024 VS 2034
2.6 Global Klebsiella Pneumoniae Infection Drug Sales Quantity by Region
2.6.1 Global Klebsiella Pneumoniae Infection Drug Sales Quantity by Region (2018-2023)
2.6.2 Global Klebsiella Pneumoniae Infection Drug Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Klebsiella Pneumoniae Infection Drug Sales Quantity by Manufacturers
3.1.1 Global Klebsiella Pneumoniae Infection Drug Sales Quantity by Manufacturers (2018-2023)
3.1.2 Global Klebsiella Pneumoniae Infection Drug Sales Quantity Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Companies by Klebsiella Pneumoniae Infection Drug Sales in 2024
3.2 Global Klebsiella Pneumoniae Infection Drug Revenue by Manufacturers
3.2.1 Global Klebsiella Pneumoniae Infection Drug Revenue by Manufacturers (2018-2023)
3.2.2 Global Klebsiella Pneumoniae Infection Drug Revenue Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Klebsiella Pneumoniae Infection Drug Revenue in 2024
3.3 Global Klebsiella Pneumoniae Infection Drug Sales Price by Manufacturers
3.4 Global Key Players of Klebsiella Pneumoniae Infection Drug, Industry Ranking, 2021 VS 2024
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Klebsiella Pneumoniae Infection Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Klebsiella Pneumoniae Infection Drug, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Klebsiella Pneumoniae Infection Drug, Product Offered and Application
3.8 Global Key Manufacturers of Klebsiella Pneumoniae Infection Drug, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Klebsiella Pneumoniae Infection Drug Sales Quantity by Type
4.1.1 Global Klebsiella Pneumoniae Infection Drug Historical Sales Quantity by Type (2018-2023)
4.1.2 Global Klebsiella Pneumoniae Infection Drug Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Klebsiella Pneumoniae Infection Drug Sales Quantity Market Share by Type (2018-2034)
4.2 Global Klebsiella Pneumoniae Infection Drug Revenue by Type
4.2.1 Global Klebsiella Pneumoniae Infection Drug Historical Revenue by Type (2018-2023)
4.2.2 Global Klebsiella Pneumoniae Infection Drug Forecasted Revenue by Type (2024-2034)
4.2.3 Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Type (2018-2034)
4.3 Global Klebsiella Pneumoniae Infection Drug Price by Type
4.3.1 Global Klebsiella Pneumoniae Infection Drug Price by Type (2018-2023)
4.3.2 Global Klebsiella Pneumoniae Infection Drug Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Klebsiella Pneumoniae Infection Drug Sales Quantity by Application
5.1.1 Global Klebsiella Pneumoniae Infection Drug Historical Sales Quantity by Application (2018-2023)
5.1.2 Global Klebsiella Pneumoniae Infection Drug Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Klebsiella Pneumoniae Infection Drug Sales Quantity Market Share by Application (2018-2034)
5.2 Global Klebsiella Pneumoniae Infection Drug Revenue by Application
5.2.1 Global Klebsiella Pneumoniae Infection Drug Historical Revenue by Application (2018-2023)
5.2.2 Global Klebsiella Pneumoniae Infection Drug Forecasted Revenue by Application (2024-2034)
5.2.3 Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Application (2018-2034)
5.3 Global Klebsiella Pneumoniae Infection Drug Price by Application
5.3.1 Global Klebsiella Pneumoniae Infection Drug Price by Application (2018-2023)
5.3.2 Global Klebsiella Pneumoniae Infection Drug Price Forecast by Application (2024-2034)
6 North America
6.1 North America Klebsiella Pneumoniae Infection Drug Sales by Company
6.1.1 North America Klebsiella Pneumoniae Infection Drug Revenue by Company (2018-2023)
6.1.2 North America Klebsiella Pneumoniae Infection Drug Sales Quantity by Company (2018-2023)
6.2 North America Klebsiella Pneumoniae Infection Drug Market Size by Type
6.2.1 North America Klebsiella Pneumoniae Infection Drug Sales Quantity by Type (2018-2034)
6.2.2 North America Klebsiella Pneumoniae Infection Drug Revenue by Type (2018-2034)
6.3 North America Klebsiella Pneumoniae Infection Drug Market Size by Application
6.3.1 North America Klebsiella Pneumoniae Infection Drug Sales Quantity by Application (2018-2034)
6.3.2 North America Klebsiella Pneumoniae Infection Drug Revenue by Application (2018-2034)
6.4 North America Klebsiella Pneumoniae Infection Drug Market Size by Country
6.4.1 North America Klebsiella Pneumoniae Infection Drug Revenue by Country: 2018 VS 2024 VS 2034
6.4.2 North America Klebsiella Pneumoniae Infection Drug Revenue by Country (2018-2034)
6.4.3 North America Klebsiella Pneumoniae Infection Drug Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Klebsiella Pneumoniae Infection Drug Sales by Company
7.1.1 Europe Klebsiella Pneumoniae Infection Drug Sales Quantity by Company (2018-2023)
7.1.2 Europe Klebsiella Pneumoniae Infection Drug Revenue by Company (2018-2023)
7.2 Europe Klebsiella Pneumoniae Infection Drug Market Size by Type
7.2.1 Europe Klebsiella Pneumoniae Infection Drug Sales Quantity by Type (2018-2034)
7.2.2 Europe Klebsiella Pneumoniae Infection Drug Revenue by Type (2018-2034)
7.3 Europe Klebsiella Pneumoniae Infection Drug Market Size by Application
7.3.1 Europe Klebsiella Pneumoniae Infection Drug Sales Quantity by Application (2018-2034)
7.3.2 Europe Klebsiella Pneumoniae Infection Drug Revenue by Application (2018-2034)
7.4 Europe Klebsiella Pneumoniae Infection Drug Market Size by Country
7.4.1 Europe Klebsiella Pneumoniae Infection Drug Revenue by Country: 2018 VS 2024 VS 2034
7.4.2 Europe Klebsiella Pneumoniae Infection Drug Revenue by Country (2018-2034)
7.4.3 Europe Klebsiella Pneumoniae Infection Drug Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Klebsiella Pneumoniae Infection Drug Sales by Company
8.1.1 China Klebsiella Pneumoniae Infection Drug Sales Quantity by Company (2018-2023)
8.1.2 China Klebsiella Pneumoniae Infection Drug Revenue by Company (2018-2023)
8.2 China Klebsiella Pneumoniae Infection Drug Market Size by Type
8.2.1 China Klebsiella Pneumoniae Infection Drug Sales Quantity by Type (2018-2034)
8.2.2 China Klebsiella Pneumoniae Infection Drug Revenue by Type (2018-2034)
8.3 China Klebsiella Pneumoniae Infection Drug Market Size by Application
8.3.1 China Klebsiella Pneumoniae Infection Drug Sales Quantity by Application (2018-2034)
8.3.2 China Klebsiella Pneumoniae Infection Drug Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Klebsiella Pneumoniae Infection Drug Sales by Company
9.1.1 APAC Klebsiella Pneumoniae Infection Drug Sales Quantity by Company (2018-2023)
9.1.2 APAC Klebsiella Pneumoniae Infection Drug Revenue by Company (2018-2023)
9.2 APAC Klebsiella Pneumoniae Infection Drug Market Size by Type
9.2.1 APAC Klebsiella Pneumoniae Infection Drug Sales Quantity by Type (2018-2034)
9.2.2 APAC Klebsiella Pneumoniae Infection Drug Revenue by Type (2018-2034)
9.3 APAC Klebsiella Pneumoniae Infection Drug Market Size by Application
9.3.1 APAC Klebsiella Pneumoniae Infection Drug Sales Quantity by Application (2018-2034)
9.3.2 APAC Klebsiella Pneumoniae Infection Drug Revenue by Application (2018-2034)
9.4 APAC Klebsiella Pneumoniae Infection Drug Market Size by Region
9.4.1 APAC Klebsiella Pneumoniae Infection Drug Revenue by Region: 2018 VS 2024 VS 2034
9.4.2 APAC Klebsiella Pneumoniae Infection Drug Revenue by Region (2018-2034)
9.4.3 APAC Klebsiella Pneumoniae Infection Drug Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Klebsiella Pneumoniae Infection Drug Sales by Company
10.1.1 Middle East, Africa and Latin America Klebsiella Pneumoniae Infection Drug Sales Quantity by Company (2018-2023)
10.1.2 Middle East, Africa and Latin America Klebsiella Pneumoniae Infection Drug Revenue by Company (2018-2023)
10.2 Middle East, Africa and Latin America Klebsiella Pneumoniae Infection Drug Market Size by Type
10.2.1 Middle East, Africa and Latin America Klebsiella Pneumoniae Infection Drug Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Klebsiella Pneumoniae Infection Drug Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Klebsiella Pneumoniae Infection Drug Market Size by Application
10.3.1 Middle East, Africa and Latin America Klebsiella Pneumoniae Infection Drug Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Klebsiella Pneumoniae Infection Drug Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Klebsiella Pneumoniae Infection Drug Market Size by Country
10.4.1 Middle East, Africa and Latin America Klebsiella Pneumoniae Infection Drug Revenue by Country: 2018 VS 2024 VS 2034
10.4.2 Middle East, Africa and Latin America Klebsiella Pneumoniae Infection Drug Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Klebsiella Pneumoniae Infection Drug Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Acies Bio doo
11.1.1 Acies Bio doo Company Information
11.1.2 Acies Bio doo Overview
11.1.3 Acies Bio doo Klebsiella Pneumoniae Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.1.4 Acies Bio doo Klebsiella Pneumoniae Infection Drug Products and Services
11.1.5 Acies Bio doo Klebsiella Pneumoniae Infection Drug SWOT Analysis
11.1.6 Acies Bio doo Recent Developments
11.2 Appili Therapeutics
11.2.1 Appili Therapeutics Company Information
11.2.2 Appili Therapeutics Overview
11.2.3 Appili Therapeutics Klebsiella Pneumoniae Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.2.4 Appili Therapeutics Klebsiella Pneumoniae Infection Drug Products and Services
11.2.5 Appili Therapeutics Klebsiella Pneumoniae Infection Drug SWOT Analysis
11.2.6 Appili Therapeutics Recent Developments
11.3 Debiopharm International SA
11.3.1 Debiopharm International SA Company Information
11.3.2 Debiopharm International SA Overview
11.3.3 Debiopharm International SA Klebsiella Pneumoniae Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.3.4 Debiopharm International SA Klebsiella Pneumoniae Infection Drug Products and Services
11.3.5 Debiopharm International SA Klebsiella Pneumoniae Infection Drug SWOT Analysis
11.3.6 Debiopharm International SA Recent Developments
11.4 Evaxion Biotech ApS
11.4.1 Evaxion Biotech ApS Company Information
11.4.2 Evaxion Biotech ApS Overview
11.4.3 Evaxion Biotech ApS Klebsiella Pneumoniae Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.4.4 Evaxion Biotech ApS Klebsiella Pneumoniae Infection Drug Products and Services
11.4.5 Evaxion Biotech ApS Klebsiella Pneumoniae Infection Drug SWOT Analysis
11.4.6 Evaxion Biotech ApS Recent Developments
11.5 F. Hoffmann-La Roche Ltd
11.5.1 F. Hoffmann-La Roche Ltd Company Information
11.5.2 F. Hoffmann-La Roche Ltd Overview
11.5.3 F. Hoffmann-La Roche Ltd Klebsiella Pneumoniae Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.5.4 F. Hoffmann-La Roche Ltd Klebsiella Pneumoniae Infection Drug Products and Services
11.5.5 F. Hoffmann-La Roche Ltd Klebsiella Pneumoniae Infection Drug SWOT Analysis
11.5.6 F. Hoffmann-La Roche Ltd Recent Developments
11.6 FOB Synthesis Inc
11.6.1 FOB Synthesis Inc Company Information
11.6.2 FOB Synthesis Inc Overview
11.6.3 FOB Synthesis Inc Klebsiella Pneumoniae Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.6.4 FOB Synthesis Inc Klebsiella Pneumoniae Infection Drug Products and Services
11.6.5 FOB Synthesis Inc Klebsiella Pneumoniae Infection Drug SWOT Analysis
11.6.6 FOB Synthesis Inc Recent Developments
11.7 ImmunoClin Corp
11.7.1 ImmunoClin Corp Company Information
11.7.2 ImmunoClin Corp Overview
11.7.3 ImmunoClin Corp Klebsiella Pneumoniae Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.7.4 ImmunoClin Corp Klebsiella Pneumoniae Infection Drug Products and Services
11.7.5 ImmunoClin Corp Klebsiella Pneumoniae Infection Drug SWOT Analysis
11.7.6 ImmunoClin Corp Recent Developments
11.8 Innovation Pharmaceuticals Inc
11.8.1 Innovation Pharmaceuticals Inc Company Information
11.8.2 Innovation Pharmaceuticals Inc Overview
11.8.3 Innovation Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.8.4 Innovation Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Products and Services
11.8.5 Innovation Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug SWOT Analysis
11.8.6 Innovation Pharmaceuticals Inc Recent Developments
11.9 Kyorin Pharmaceutical Co Ltd
11.9.1 Kyorin Pharmaceutical Co Ltd Company Information
11.9.2 Kyorin Pharmaceutical Co Ltd Overview
11.9.3 Kyorin Pharmaceutical Co Ltd Klebsiella Pneumoniae Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.9.4 Kyorin Pharmaceutical Co Ltd Klebsiella Pneumoniae Infection Drug Products and Services
11.9.5 Kyorin Pharmaceutical Co Ltd Klebsiella Pneumoniae Infection Drug SWOT Analysis
11.9.6 Kyorin Pharmaceutical Co Ltd Recent Developments
11.10 Melinta Therapeutics Inc
11.10.1 Melinta Therapeutics Inc Company Information
11.10.2 Melinta Therapeutics Inc Overview
11.10.3 Melinta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.10.4 Melinta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Products and Services
11.10.5 Melinta Therapeutics Inc Klebsiella Pneumoniae Infection Drug SWOT Analysis
11.10.6 Melinta Therapeutics Inc Recent Developments
11.11 Nosopharm SAS
11.11.1 Nosopharm SAS Company Information
11.11.2 Nosopharm SAS Overview
11.11.3 Nosopharm SAS Klebsiella Pneumoniae Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.11.4 Nosopharm SAS Klebsiella Pneumoniae Infection Drug Products and Services
11.11.5 Nosopharm SAS Recent Developments
11.12 Peptilogics Inc
11.12.1 Peptilogics Inc Company Information
11.12.2 Peptilogics Inc Overview
11.12.3 Peptilogics Inc Klebsiella Pneumoniae Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.12.4 Peptilogics Inc Klebsiella Pneumoniae Infection Drug Products and Services
11.12.5 Peptilogics Inc Recent Developments
11.13 Pfizer Inc
11.13.1 Pfizer Inc Company Information
11.13.2 Pfizer Inc Overview
11.13.3 Pfizer Inc Klebsiella Pneumoniae Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.13.4 Pfizer Inc Klebsiella Pneumoniae Infection Drug Products and Services
11.13.5 Pfizer Inc Recent Developments
11.14 Phico Therapeutics Ltd
11.14.1 Phico Therapeutics Ltd Company Information
11.14.2 Phico Therapeutics Ltd Overview
11.14.3 Phico Therapeutics Ltd Klebsiella Pneumoniae Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.14.4 Phico Therapeutics Ltd Klebsiella Pneumoniae Infection Drug Products and Services
11.14.5 Phico Therapeutics Ltd Recent Developments
11.15 Sarepta Therapeutics Inc
11.15.1 Sarepta Therapeutics Inc Company Information
11.15.2 Sarepta Therapeutics Inc Overview
11.15.3 Sarepta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.15.4 Sarepta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Products and Services
11.15.5 Sarepta Therapeutics Inc Recent Developments
11.16 Shionogi & Co Ltd
11.16.1 Shionogi & Co Ltd Company Information
11.16.2 Shionogi & Co Ltd Overview
11.16.3 Shionogi & Co Ltd Klebsiella Pneumoniae Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.16.4 Shionogi & Co Ltd Klebsiella Pneumoniae Infection Drug Products and Services
11.16.5 Shionogi & Co Ltd Recent Developments
11.17 Syntiron LLC
11.17.1 Syntiron LLC Company Information
11.17.2 Syntiron LLC Overview
11.17.3 Syntiron LLC Klebsiella Pneumoniae Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.17.4 Syntiron LLC Klebsiella Pneumoniae Infection Drug Products and Services
11.17.5 Syntiron LLC Recent Developments
11.18 Tetraphase Pharmaceuticals Inc
11.18.1 Tetraphase Pharmaceuticals Inc Company Information
11.18.2 Tetraphase Pharmaceuticals Inc Overview
11.18.3 Tetraphase Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.18.4 Tetraphase Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Products and Services
11.18.5 Tetraphase Pharmaceuticals Inc Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Klebsiella Pneumoniae Infection Drug Value Chain Analysis
12.2 Klebsiella Pneumoniae Infection Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Klebsiella Pneumoniae Infection Drug Production Mode & Process
12.4 Klebsiella Pneumoniae Infection Drug Sales and Marketing
12.4.1 Klebsiella Pneumoniae Infection Drug Sales Channels
12.4.2 Klebsiella Pneumoniae Infection Drug Distributors
12.5 Klebsiella Pneumoniae Infection Drug Customers
13 Market Dynamics
13.1 Klebsiella Pneumoniae Infection Drug Industry Trends
13.2 Klebsiella Pneumoniae Infection Drug Market Drivers
13.3 Klebsiella Pneumoniae Infection Drug Market Challenges
13.4 Klebsiella Pneumoniae Infection Drug Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Klebsiella Pneumoniae Infection Drug Market Size Growth Rate (CAGR) by Type, 2018 VS 2024 VS 2034 (US$ Million)
Table 2. Major Manufacturers of ATI-1503
Table 3. Major Manufacturers of CA-824
Table 4. Major Manufacturers of CC-1807
Table 5. Major Manufacturers of Cefiderocol
Table 6. Major Manufacturers of Debio-1454
Table 7. Major Manufacturers of EBX-004
Table 8. Major Manufacturers of Others
Table 9. Global Klebsiella Pneumoniae Infection Drug Market Size Growth Rate (CAGR) by Application, 2018 VS 2024 VS 2034 (US$ Million)
Table 10. Global Klebsiella Pneumoniae Infection Drug Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 11. Global Klebsiella Pneumoniae Infection Drug Revenue by Region (2018-2023) & (US$ Million)
Table 12. Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Region (2018-2023)
Table 13. Global Klebsiella Pneumoniae Infection Drug Revenue by Region (2024-2034) & (US$ Million)
Table 14. Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Region (2024-2034)
Table 15. Global Klebsiella Pneumoniae Infection Drug Sales Quantity by Region: 2018 VS 2024 VS 2034 (K Pcs)
Table 16. Global Klebsiella Pneumoniae Infection Drug Sales by Region (2018-2023) & (K Pcs)
Table 17. Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Region (2018-2023)
Table 18. Global Klebsiella Pneumoniae Infection Drug Sales by Region (2024-2034) & (K Pcs)
Table 19. Global Klebsiella Pneumoniae Infection Drug Sales Market Share by Region (2024-2034)
Table 20. Global Klebsiella Pneumoniae Infection Drug Sales Quantity by Manufacturers (2018-2023) & (K Pcs)
Table 21. Global Klebsiella Pneumoniae Infection Drug Sales Quantity Share by Manufacturers (2018-2023)
Table 22. Global Klebsiella Pneumoniae Infection Drug Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 23. Global Klebsiella Pneumoniae Infection Drug Revenue Share by Manufacturers (2018-2023)
Table 24. Global Klebsiella Pneumoniae Infection Drug Price by Manufacturers 2018-2023 (USD/Pcs)
Table 25. Global Key Players of Klebsiella Pneumoniae Infection Drug, Industry Ranking, 2021 VS 2024
Table 26. Global Klebsiella Pneumoniae Infection Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 27. Global Klebsiella Pneumoniae Infection Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Klebsiella Pneumoniae Infection Drug as of 2024)
Table 28. Global Key Manufacturers of Klebsiella Pneumoniae Infection Drug, Manufacturing Base Distribution and Headquarters
Table 29. Global Key Manufacturers of Klebsiella Pneumoniae Infection Drug, Product Offered and Application
Table 30. Global Key Manufacturers of Klebsiella Pneumoniae Infection Drug, Date of Enter into This Industry
Table 31. Mergers & Acquisitions, Expansion Plans
Table 32. Global Klebsiella Pneumoniae Infection Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 33. Global Klebsiella Pneumoniae Infection Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 34. Global Klebsiella Pneumoniae Infection Drug Sales Quantity Share by Type (2018-2023)
Table 35. Global Klebsiella Pneumoniae Infection Drug Sales Quantity Share by Type (2024-2034)
Table 36. Global Klebsiella Pneumoniae Infection Drug Revenue by Type (2018-2023) & (US$ Million)
Table 37. Global Klebsiella Pneumoniae Infection Drug Revenue by Type (2024-2034) & (US$ Million)
Table 38. Global Klebsiella Pneumoniae Infection Drug Revenue Share by Type (2018-2023)
Table 39. Global Klebsiella Pneumoniae Infection Drug Revenue Share by Type (2024-2034)
Table 40. Klebsiella Pneumoniae Infection Drug Price by Type (2018-2023) & (USD/Pcs)
Table 41. Global Klebsiella Pneumoniae Infection Drug Price Forecast by Type (2024-2034) & (USD/Pcs)
Table 42. Global Klebsiella Pneumoniae Infection Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 43. Global Klebsiella Pneumoniae Infection Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 44. Global Klebsiella Pneumoniae Infection Drug Sales Quantity Share by Application (2018-2023)
Table 45. Global Klebsiella Pneumoniae Infection Drug Sales Quantity Share by Application (2024-2034)
Table 46. Global Klebsiella Pneumoniae Infection Drug Revenue by Application (2018-2023) & (US$ Million)
Table 47. Global Klebsiella Pneumoniae Infection Drug Revenue by Application (2024-2034) & (US$ Million)
Table 48. Global Klebsiella Pneumoniae Infection Drug Revenue Share by Application (2018-2023)
Table 49. Global Klebsiella Pneumoniae Infection Drug Revenue Share by Application (2024-2034)
Table 50. Klebsiella Pneumoniae Infection Drug Price by Application (2018-2023) & (USD/Pcs)
Table 51. Global Klebsiella Pneumoniae Infection Drug Price Forecast by Application (2024-2034) & (USD/Pcs)
Table 52. North America Klebsiella Pneumoniae Infection Drug Revenue by Company (2018-2023) & (US$ Million)
Table 53. North America Klebsiella Pneumoniae Infection Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 54. North America Klebsiella Pneumoniae Infection Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 55. North America Klebsiella Pneumoniae Infection Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 56. North America Klebsiella Pneumoniae Infection Drug Revenue by Type (2018-2023) & (US$ Million)
Table 57. North America Klebsiella Pneumoniae Infection Drug Revenue by Type (2024-2034) & (US$ Million)
Table 58. North America Klebsiella Pneumoniae Infection Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 59. North America Klebsiella Pneumoniae Infection Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 60. North America Klebsiella Pneumoniae Infection Drug Revenue by Application (2018-2023) & (US$ Million)
Table 61. North America Klebsiella Pneumoniae Infection Drug Revenue by Application (2024-2034) & (US$ Million)
Table 62. North America Klebsiella Pneumoniae Infection Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 63. North America Klebsiella Pneumoniae Infection Drug Revenue by Country (2018-2023) & (US$ Million)
Table 64. North America Klebsiella Pneumoniae Infection Drug Revenue by Country (2024-2034) & (US$ Million)
Table 65. North America Klebsiella Pneumoniae Infection Drug Sales Quantity by Country (2018-2023) & (K Pcs)
Table 66. North America Klebsiella Pneumoniae Infection Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 67. Europe Klebsiella Pneumoniae Infection Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 68. Europe Klebsiella Pneumoniae Infection Drug Revenue by Company (2018-2023) & (US$ Million)
Table 69. Europe Klebsiella Pneumoniae Infection Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 70. Europe Klebsiella Pneumoniae Infection Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 71. Europe Klebsiella Pneumoniae Infection Drug Revenue by Type (2018-2023) & (US$ Million)
Table 72. Europe Klebsiella Pneumoniae Infection Drug Revenue by Type (2024-2034) & (US$ Million)
Table 73. Europe Klebsiella Pneumoniae Infection Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 74. Europe Klebsiella Pneumoniae Infection Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 75. Europe Klebsiella Pneumoniae Infection Drug Revenue by Application (2018-2023) & (US$ Million)
Table 76. Europe Klebsiella Pneumoniae Infection Drug Revenue by Application (2024-2034) & (US$ Million)
Table 77. Europe Klebsiella Pneumoniae Infection Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 78. Europe Klebsiella Pneumoniae Infection Drug Revenue by Country (2018-2023) & (US$ Million)
Table 79. Europe Klebsiella Pneumoniae Infection Drug Revenue by Country (2024-2034) & (US$ Million)
Table 80. Europe Klebsiella Pneumoniae Infection Drug Sales Quantity by Country (2018-2023) & (K Pcs)
Table 81. Europe Klebsiella Pneumoniae Infection Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 82. China Klebsiella Pneumoniae Infection Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 83. China Klebsiella Pneumoniae Infection Drug Revenue by Company (2018-2023) & (US$ Million)
Table 84. China Klebsiella Pneumoniae Infection Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 85. China Klebsiella Pneumoniae Infection Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 86. China Klebsiella Pneumoniae Infection Drug Revenue by Type (2018-2023) & (US$ Million)
Table 87. China Klebsiella Pneumoniae Infection Drug Revenue by Type (2024-2034) & (US$ Million)
Table 88. China Klebsiella Pneumoniae Infection Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 89. China Klebsiella Pneumoniae Infection Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 90. China Klebsiella Pneumoniae Infection Drug Revenue by Application (2018-2023) & (US$ Million)
Table 91. China Klebsiella Pneumoniae Infection Drug Revenue by Application (2024-2034) & (US$ Million)
Table 92. APAC Klebsiella Pneumoniae Infection Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 93. APAC Klebsiella Pneumoniae Infection Drug Revenue by Company (2018-2023) & (US$ Million)
Table 94. APAC Klebsiella Pneumoniae Infection Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 95. APAC Klebsiella Pneumoniae Infection Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 96. APAC Klebsiella Pneumoniae Infection Drug Revenue by Type (2018-2023) & (US$ Million)
Table 97. APAC Klebsiella Pneumoniae Infection Drug Revenue by Type (2024-2034) & (US$ Million)
Table 98. APAC Klebsiella Pneumoniae Infection Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 99. APAC Klebsiella Pneumoniae Infection Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 100. APAC Klebsiella Pneumoniae Infection Drug Revenue by Application (2018-2023) & (US$ Million)
Table 101. APAC Klebsiella Pneumoniae Infection Drug Revenue by Application (2024-2034) & (US$ Million)
Table 102. APAC Klebsiella Pneumoniae Infection Drug Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 103. APAC Klebsiella Pneumoniae Infection Drug Revenue by Region (2018-2023) & (US$ Million)
Table 104. APAC Klebsiella Pneumoniae Infection Drug Revenue by Region (2024-2034) & (US$ Million)
Table 105. APAC Klebsiella Pneumoniae Infection Drug Sales Quantity by Region (2018-2023) & (K Pcs)
Table 106. APAC Klebsiella Pneumoniae Infection Drug Sales Quantity by Region (2024-2034) & (K Pcs)
Table 107. Middle East, Africa and Latin America Klebsiella Pneumoniae Infection Drug Sales Quantity by Company (2018-2023) & (K Pcs)
Table 108. Middle East, Africa and Latin America Klebsiella Pneumoniae Infection Drug Revenue by Company (2018-2023) & (US$ Million)
Table 109. Middle East, Africa and Latin America Klebsiella Pneumoniae Infection Drug Sales Quantity by Type (2018-2023) & (K Pcs)
Table 110. Middle East, Africa and Latin America Klebsiella Pneumoniae Infection Drug Sales Quantity by Type (2024-2034) & (K Pcs)
Table 111. Middle East, Africa and Latin America Klebsiella Pneumoniae Infection Drug Revenue by Type (2018-2023) & (US$ Million)
Table 112. Middle East, Africa and Latin America Klebsiella Pneumoniae Infection Drug Revenue by Type (2024-2034) & (US$ Million)
Table 113. Middle East, Africa and Latin America Klebsiella Pneumoniae Infection Drug Sales Quantity by Application (2018-2023) & (K Pcs)
Table 114. Middle East, Africa and Latin America Klebsiella Pneumoniae Infection Drug Sales Quantity by Application (2024-2034) & (K Pcs)
Table 115. Middle East, Africa and Latin America Klebsiella Pneumoniae Infection Drug Revenue by Application (2018-2023) & (US$ Million)
Table 116. Middle East, Africa and Latin America Klebsiella Pneumoniae Infection Drug Revenue by Application (2024-2034) & (US$ Million)
Table 117. Middle East, Africa and Latin America Klebsiella Pneumoniae Infection Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 118. Middle East, Africa and Latin America Klebsiella Pneumoniae Infection Drug Revenue by Country (2018-2023) & (US$ Million)
Table 119. Middle East, Africa and Latin America Klebsiella Pneumoniae Infection Drug Revenue by Country (2024-2034) & (US$ Million)
Table 120. Middle East, Africa and Latin America Klebsiella Pneumoniae Infection Drug Sales Quantity by Country (2018-2023) & (K Pcs)
Table 121. Middle East, Africa and Latin America Klebsiella Pneumoniae Infection Drug Sales Quantity by Country (2024-2034) & (K Pcs)
Table 122. Acies Bio doo Company Information
Table 123. Acies Bio doo Description and Overview
Table 124. Acies Bio doo Klebsiella Pneumoniae Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 125. Acies Bio doo Klebsiella Pneumoniae Infection Drug Product and Services
Table 126. Acies Bio doo Klebsiella Pneumoniae Infection Drug SWOT Analysis
Table 127. Acies Bio doo Recent Developments
Table 128. Appili Therapeutics Company Information
Table 129. Appili Therapeutics Description and Overview
Table 130. Appili Therapeutics Klebsiella Pneumoniae Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 131. Appili Therapeutics Klebsiella Pneumoniae Infection Drug Product and Services
Table 132. Appili Therapeutics Klebsiella Pneumoniae Infection Drug SWOT Analysis
Table 133. Appili Therapeutics Recent Developments
Table 134. Debiopharm International SA Company Information
Table 135. Debiopharm International SA Description and Overview
Table 136. Debiopharm International SA Klebsiella Pneumoniae Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 137. Debiopharm International SA Klebsiella Pneumoniae Infection Drug Product and Services
Table 138. Debiopharm International SA Klebsiella Pneumoniae Infection Drug SWOT Analysis
Table 139. Debiopharm International SA Recent Developments
Table 140. Evaxion Biotech ApS Company Information
Table 141. Evaxion Biotech ApS Description and Overview
Table 142. Evaxion Biotech ApS Klebsiella Pneumoniae Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 143. Evaxion Biotech ApS Klebsiella Pneumoniae Infection Drug Product and Services
Table 144. Evaxion Biotech ApS Klebsiella Pneumoniae Infection Drug SWOT Analysis
Table 145. Evaxion Biotech ApS Recent Developments
Table 146. F. Hoffmann-La Roche Ltd Company Information
Table 147. F. Hoffmann-La Roche Ltd Description and Overview
Table 148. F. Hoffmann-La Roche Ltd Klebsiella Pneumoniae Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 149. F. Hoffmann-La Roche Ltd Klebsiella Pneumoniae Infection Drug Product and Services
Table 150. F. Hoffmann-La Roche Ltd Klebsiella Pneumoniae Infection Drug SWOT Analysis
Table 151. F. Hoffmann-La Roche Ltd Recent Developments
Table 152. FOB Synthesis Inc Company Information
Table 153. FOB Synthesis Inc Description and Overview
Table 154. FOB Synthesis Inc Klebsiella Pneumoniae Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 155. FOB Synthesis Inc Klebsiella Pneumoniae Infection Drug Product and Services
Table 156. FOB Synthesis Inc Klebsiella Pneumoniae Infection Drug SWOT Analysis
Table 157. FOB Synthesis Inc Recent Developments
Table 158. ImmunoClin Corp Company Information
Table 159. ImmunoClin Corp Description and Overview
Table 160. ImmunoClin Corp Klebsiella Pneumoniae Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 161. ImmunoClin Corp Klebsiella Pneumoniae Infection Drug Product and Services
Table 162. ImmunoClin Corp Klebsiella Pneumoniae Infection Drug SWOT Analysis
Table 163. ImmunoClin Corp Recent Developments
Table 164. Innovation Pharmaceuticals Inc Company Information
Table 165. Innovation Pharmaceuticals Inc Description and Overview
Table 166. Innovation Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 167. Innovation Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Product and Services
Table 168. Innovation Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug SWOT Analysis
Table 169. Innovation Pharmaceuticals Inc Recent Developments
Table 170. Kyorin Pharmaceutical Co Ltd Company Information
Table 171. Kyorin Pharmaceutical Co Ltd Description and Overview
Table 172. Kyorin Pharmaceutical Co Ltd Klebsiella Pneumoniae Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 173. Kyorin Pharmaceutical Co Ltd Klebsiella Pneumoniae Infection Drug Product and Services
Table 174. Kyorin Pharmaceutical Co Ltd Klebsiella Pneumoniae Infection Drug SWOT Analysis
Table 175. Kyorin Pharmaceutical Co Ltd Recent Developments
Table 176. Melinta Therapeutics Inc Company Information
Table 177. Melinta Therapeutics Inc Description and Overview
Table 178. Melinta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 179. Melinta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Product and Services
Table 180. Melinta Therapeutics Inc Klebsiella Pneumoniae Infection Drug SWOT Analysis
Table 181. Melinta Therapeutics Inc Recent Developments
Table 182. Nosopharm SAS Company Information
Table 183. Nosopharm SAS Description and Overview
Table 184. Nosopharm SAS Klebsiella Pneumoniae Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 185. Nosopharm SAS Klebsiella Pneumoniae Infection Drug Product and Services
Table 186. Nosopharm SAS Recent Developments
Table 187. Peptilogics Inc Company Information
Table 188. Peptilogics Inc Description and Overview
Table 189. Peptilogics Inc Klebsiella Pneumoniae Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 190. Peptilogics Inc Klebsiella Pneumoniae Infection Drug Product and Services
Table 191. Peptilogics Inc Recent Developments
Table 192. Pfizer Inc Company Information
Table 193. Pfizer Inc Description and Overview
Table 194. Pfizer Inc Klebsiella Pneumoniae Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 195. Pfizer Inc Klebsiella Pneumoniae Infection Drug Product and Services
Table 196. Pfizer Inc Recent Developments
Table 197. Phico Therapeutics Ltd Company Information
Table 198. Phico Therapeutics Ltd Description and Overview
Table 199. Phico Therapeutics Ltd Klebsiella Pneumoniae Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 200. Phico Therapeutics Ltd Klebsiella Pneumoniae Infection Drug Product and Services
Table 201. Phico Therapeutics Ltd Recent Developments
Table 202. Sarepta Therapeutics Inc Company Information
Table 203. Sarepta Therapeutics Inc Description and Overview
Table 204. Sarepta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 205. Sarepta Therapeutics Inc Klebsiella Pneumoniae Infection Drug Product and Services
Table 206. Sarepta Therapeutics Inc Recent Developments
Table 207. Shionogi & Co Ltd Company Information
Table 208. Shionogi & Co Ltd Description and Overview
Table 209. Shionogi & Co Ltd Klebsiella Pneumoniae Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 210. Shionogi & Co Ltd Klebsiella Pneumoniae Infection Drug Product and Services
Table 211. Shionogi & Co Ltd Recent Developments
Table 212. Syntiron LLC Company Information
Table 213. Syntiron LLC Description and Overview
Table 214. Syntiron LLC Klebsiella Pneumoniae Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 215. Syntiron LLC Klebsiella Pneumoniae Infection Drug Product and Services
Table 216. Syntiron LLC Recent Developments
Table 217. Tetraphase Pharmaceuticals Inc Company Information
Table 218. Tetraphase Pharmaceuticals Inc Description and Overview
Table 219. Tetraphase Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Sales Quantity (K Pcs), Revenue (US$ Million), Average Selling Price (ASP) (USD/Pcs) and Gross Margin (2018-2023)
Table 220. Tetraphase Pharmaceuticals Inc Klebsiella Pneumoniae Infection Drug Product and Services
Table 221. Tetraphase Pharmaceuticals Inc Recent Developments
Table 222. Key Raw Materials Lists
Table 223. Raw Materials Key Suppliers Lists
Table 224. Klebsiella Pneumoniae Infection Drug Distributors List
Table 225. Klebsiella Pneumoniae Infection Drug Customers List
Table 226. Klebsiella Pneumoniae Infection Drug Market Trends
Table 227. Klebsiella Pneumoniae Infection Drug Market Drivers
Table 228. Klebsiella Pneumoniae Infection Drug Market Challenges
Table 229. Klebsiella Pneumoniae Infection Drug Market Restraints
Table 230. Research Programs/Design for This Report
Table 231. Key Data Information from Secondary Sources
Table 232. Key Data Information from Primary Sources
List of Figures
Figure 1. Klebsiella Pneumoniae Infection Drug Product Picture
Figure 2. Global Klebsiella Pneumoniae Infection Drug Market Size Growth Rate by Type, 2018 VS 2024 VS 2034 (US$ Million)
Figure 3. Global Klebsiella Pneumoniae Infection Drug Market Share by Type in 2024 & 2034
Figure 4. ATI-1503 Product Picture
Figure 5. CA-824 Product Picture
Figure 6. CC-1807 Product Picture
Figure 7. Cefiderocol Product Picture
Figure 8. Debio-1454 Product Picture
Figure 9. EBX-004 Product Picture
Figure 10. Others Product Picture
Figure 11. Global Klebsiella Pneumoniae Infection Drug Market Size Growth Rate by Application, 2018 VS 2024 VS 2034 (US$ Million)
Figure 12. Global Klebsiella Pneumoniae Infection Drug Market Share by Application in 2024 & 2034
Figure 13. Hospital
Figure 14. Clinic
Figure 15. Others
Figure 16. Klebsiella Pneumoniae Infection Drug Report Years Considered
Figure 17. Global Klebsiella Pneumoniae Infection Drug Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 18. Global Klebsiella Pneumoniae Infection Drug Revenue 2018-2034 (US$ Million)
Figure 19. Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Region in Percentage: 2024 Versus 2034
Figure 20. Global Klebsiella Pneumoniae Infection Drug Sales Quantity 2018-2034 (K Pcs)
Figure 21. Global Klebsiella Pneumoniae Infection Drug Sales Quantity Market Share by Region (2018-2023)
Figure 22. Global Klebsiella Pneumoniae Infection Drug Sales Quantity Market Share by Region (2024-2034)
Figure 23. North America Klebsiella Pneumoniae Infection Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 24. North America Klebsiella Pneumoniae Infection Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 25. Europe Klebsiella Pneumoniae Infection Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 26. Europe Klebsiella Pneumoniae Infection Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 27. China Klebsiella Pneumoniae Infection Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 28. China Klebsiella Pneumoniae Infection Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 29. APAC Klebsiella Pneumoniae Infection Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 30. APAC Klebsiella Pneumoniae Infection Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 31. Middle East, Africa and Latin America Klebsiella Pneumoniae Infection Drug Sales Quantity YoY (2018-2034) & (K Pcs)
Figure 32. Middle East, Africa and Latin America Klebsiella Pneumoniae Infection Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 33. The Top 10 and Top 5 Players Market Share by Klebsiella Pneumoniae Infection Drug Sales Quantity in 2024
Figure 34. The Top 10 and Top 5 Players Market Share by Klebsiella Pneumoniae Infection Drug Revenue in 2024
Figure 35. Klebsiella Pneumoniae Infection Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2024
Figure 36. Global Klebsiella Pneumoniae Infection Drug Sales Quantity Market Share by Type (2018-2034)
Figure 37. Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Type (2018-2034)
Figure 38. Global Klebsiella Pneumoniae Infection Drug Sales Quantity Market Share by Application (2018-2034)
Figure 39. Global Klebsiella Pneumoniae Infection Drug Revenue Market Share by Application (2018-2034)
Figure 40. North America Klebsiella Pneumoniae Infection Drug Revenue Market Share by Company in 2024
Figure 41. North America Klebsiella Pneumoniae Infection Drug Sales Quantity Market Share by Company in 2024
Figure 42. North America Klebsiella Pneumoniae Infection Drug Sales Quantity Market Share by Type (2018-2034)
Figure 43. North America Klebsiella Pneumoniae Infection Drug Revenue Market Share by Type (2018-2034)
Figure 44. North America Klebsiella Pneumoniae Infection Drug Sales Quantity Market Share by Application (2018-2034)
Figure 45. North America Klebsiella Pneumoniae Infection Drug Revenue Market Share by Application (2018-2034)
Figure 46. North America Klebsiella Pneumoniae Infection Drug Revenue Share by Country (2018-2034)
Figure 47. North America Klebsiella Pneumoniae Infection Drug Sales Quantity Share by Country (2018-2034)
Figure 48. U.S. Klebsiella Pneumoniae Infection Drug Revenue (2018-2034) & (US$ Million)
Figure 49. Canada Klebsiella Pneumoniae Infection Drug Revenue (2018-2034) & (US$ Million)
Figure 50. Europe Klebsiella Pneumoniae Infection Drug Sales Quantity Market Share by Company in 2024
Figure 51. Europe Klebsiella Pneumoniae Infection Drug Revenue Market Share by Company in 2024
Figure 52. Europe Klebsiella Pneumoniae Infection Drug Sales Quantity Market Share by Type (2018-2034)
Figure 53. Europe Klebsiella Pneumoniae Infection Drug Revenue Market Share by Type (2018-2034)
Figure 54. Europe Klebsiella Pneumoniae Infection Drug Sales Quantity Market Share by Application (2018-2034)
Figure 55. Europe Klebsiella Pneumoniae Infection Drug Revenue Market Share by Application (2018-2034)
Figure 56. Europe Klebsiella Pneumoniae Infection Drug Revenue Share by Country (2018-2034)
Figure 57. Europe Klebsiella Pneumoniae Infection Drug Sales Quantity Share by Country (2018-2034)
Figure 58. Germany Klebsiella Pneumoniae Infection Drug Revenue (2018-2034) & (US$ Million)
Figure 59. France Klebsiella Pneumoniae Infection Drug Revenue (2018-2034) & (US$ Million)
Figure 60. U.K. Klebsiella Pneumoniae Infection Drug Revenue (2018-2034) & (US$ Million)
Figure 61. Italy Klebsiella Pneumoniae Infection Drug Revenue (2018-2034) & (US$ Million)
Figure 62. Russia Klebsiella Pneumoniae Infection Drug Revenue (2018-2034) & (US$ Million)
Figure 63. China Klebsiella Pneumoniae Infection Drug Sales Quantity Market Share by Company in 2024
Figure 64. China Klebsiella Pneumoniae Infection Drug Revenue Market Share by Company in 2024
Figure 65. China Klebsiella Pneumoniae Infection Drug Sales Quantity Market Share by Type (2018-2034)
Figure 66. China Klebsiella Pneumoniae Infection Drug Revenue Market Share by Type (2018-2034)
Figure 67. China Klebsiella Pneumoniae Infection Drug Sales Quantity Market Share by Application (2018-2034)
Figure 68. China Klebsiella Pneumoniae Infection Drug Revenue Market Share by Application (2018-2034)
Figure 69. APAC Klebsiella Pneumoniae Infection Drug Sales Quantity Market Share by Company in 2024
Figure 70. APAC Klebsiella Pneumoniae Infection Drug Revenue Market Share by Company in 2024
Figure 71. APAC Klebsiella Pneumoniae Infection Drug Sales Quantity Market Share by Type (2018-2034)
Figure 72. APAC Klebsiella Pneumoniae Infection Drug Revenue Market Share by Type (2018-2034)
Figure 73. APAC Klebsiella Pneumoniae Infection Drug Sales Quantity Market Share by Application (2018-2034)
Figure 74. APAC Klebsiella Pneumoniae Infection Drug Revenue Market Share by Application (2018-2034)
Figure 75. APAC Klebsiella Pneumoniae Infection Drug Revenue Share by Region (2018-2034)
Figure 76. APAC Klebsiella Pneumoniae Infection Drug Sales Quantity Share by Region (2018-2034)
Figure 77. Japan Klebsiella Pneumoniae Infection Drug Revenue (2018-2034) & (US$ Million)
Figure 78. South Korea Klebsiella Pneumoniae Infection Drug Revenue (2018-2034) & (US$ Million)
Figure 79. China Taiwan Klebsiella Pneumoniae Infection Drug Revenue (2018-2034) & (US$ Million)
Figure 80. Southeast Asia Klebsiella Pneumoniae Infection Drug Revenue (2018-2034) & (US$ Million)
Figure 81. India Klebsiella Pneumoniae Infection Drug Revenue (2018-2034) & (US$ Million)
Figure 82. Middle East, Africa and Latin America Klebsiella Pneumoniae Infection Drug Sales Quantity Ma